INTRODUCTION
============

Rationale
---------

Recurrent spontaneous abortion (RSA) and pregnancy loss have different pathogeneses, consisting of genetic and chromosomal abnormalities ([@r13]), environmental toxicities and oxidative stress ([@r10]), infectious agents ([@r3]), hormonal causes, etc. Among them, immunological causes and their involving molecules are still controversial and unknown topics. The immune system is a fascinating system, one that does not normally reject the semi-allograft fetus. The immune system has two roles in implantation and pregnancy; preventing the formation of abnormal embryos, and protecting the fetomaternal interaction by releasing angiogenic factors, cytokines and adhesive molecules. The fascinating point is how a system can have two mutually exclusive features; protection and rejection. Indeed, the immune system is the bodyguard of the body through self- and non-self recognition. However, pregnancy is a semi-allograft transplantation. So the question is what the immune system does in this situation; rejection or protection ([@r1]; [@r31])?!

Immune tolerance is the best answer for the above question ([@r1]; [@r31]). Natural killer cells (NKs), which name is self-explanatory, are one of the most important lymphocytes in immune tolerance. They identify self-cells through their killer-cell immunoglobulin-like receptors (KIRs) expressed on their surface. The KIRs interact with their ligands, the human leukocyte antigens (HLAs) - the identification cards of self-cells. These interactions usually result in immune tolerance under normal conditions. Both *KIR* and *HLA* genes in human genome have loci (not locus), inherited as haplotypes. In addition, each gene in their loci is polymorphic. Thus, interaction of different KIR molecules with different HLA molecules results in different outcomes consisting of inhibitory and activating responses. *KIR* gene cluster is located on chromosome 19. This cluster has two types of genes, including 8 inhibitory and 6 activating genes, and 2 pseudogenes. Some of these genes exist in all individuals, like the *KIR2DL4*. From the viewpoint of medical anthropology, different people from different ethnicities have different KIR-HLA interactions ([@r2]; [@r4]; [@r15]; [@r18]; [@r26]).

HLA has two classes, I and II, and the class I can be further divided into classical and non-classical HLA. KIR2DL4 is an inhibitory KIR binding to the trophoblast HLA-G, which is a non-classical HLA. The combination KIR2DL4+HLA-G triggers the immune tolerance. Both *KIR2DL4* and *HLA-G* are polymorphic genes. Therefore, anthropological variations can contribute to implantation success and pregnancy maintenance. For example, HLA-G\*01:03:01 is a risk factor for implantation failure; because its connection with KIR2DL4 is not sufficient to trigger inhibitory signals ([@r17]).

NKs may have the CD16 marker, which is the weapon of antibody-depended cell-mediated cytotoxicity (ADCC). Usually CD56^dim^ NKs are CD16^+^. So CD16^+^CD56^dim^ NKs are known as cytotoxic NKs, whereas CD16^-^CD56^bright^ NKs are known as immune-regulatory NKs ([@r8]). About 90% of uterine NKs (UNKs) are immune-regulatory. In conclusion, UNKs are not usually cytotoxic for the embryo ([@r8]; [@r25]).

Objectives
----------

As we mentioned above, KIR and HLA have different genes and interactions. KIR has 8 inhibitory (*2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2* and *3DL3*) and 6 activating genes (*2DS1, 2DS2, 2DS3, 2DS4, 2DS5* and *3DS1*). Since the involving NKs in implantation of embryo are maternal, we intend to perform a meta-analysis on the role of maternal *KIR* genes diversity in RSA. Previously, [@r23]) carried out a meta-analysis on different genes, including the *KIR*. Nevertheless, their studies were few and therefore our study can serve as an update for that meta-analysis.

MATERIALS AND METHODS
=====================

Study selection
---------------

For the present meta-analysis, we searched in scientific databases such as Web of Science, PubMed, Scopus, Google Scholar, etc. Our keywords were searched only among the titles. After exclusion of duplicates, all the eligible studies were used for qualitative systematic review.

Eligibility criteria
--------------------

Among the studies imported for qualitative systematic review, only the studies with available and enough numerical data were imported for the quantitative meta-analysis. Our original paper on this topic was manually added ([Table 1](#t1){ref-type="table"}) ([@r1]). Performing *KIR* typing was the most important criterion.

###### 

Data summery of the found articles.

  Study                         Witt *et al*., 2004            Wang *et al.,* 2007            Hong *et al.*, 2008            Hiby *et al*., 2008      Vargas *et al*., 2009          Faridi *et al.*, 2009          Khosravifar *et al*., 2011     Ozturk *et al.*, 2012          Djulejic *et al*., 2015   Dambaeva *et al*., 2016   Our original study                                                                   
  ----------------------------- ------------------------------ ------------------------------ ------------------------------ ------------------------ ------------------------------ ------------------------------ ------------------------------ ------------------------------ ------------------------- ------------------------- ------------------------------ ----- ---- ---- ---- ---- ---- ----- ----- ----- ---- ----
  **2DL1**                      52                             55                             73                             68                       8                              21                             92                             258                            63                        64                        141                            215   97   95   40   89   24   115   135   189   93   95
  P value (ED) a                1 (FET) b                      1 (FET)                        0.841 (-)                      0.769 (FET) (-)          0.999 (FET) (-)                0.0001 (-)                     0.720 (+)                      1 (FET)                        1 (FET)                   1 (FET)                   0.764 (-)                                                                            
  **2DL2**                      29                             23                             22                             23                       16                             22                             45                             137                            43                        37                        110                            111   52   58   26   41   17   72    69    96          
  *p* value (ED)                0.211 (+)                      0.777 (-)                      0.002 (+)                      0.361 (-)                0.383 (+)                      0.446 (+)                      0.475 (-)                      0.632 (+)                      0.537 (+)                 1                                                                                                              
  **2DL3**                      47                             47                             72                             67                       6                              18                             88                             245                            58                        58                        169                            187   87   85   37   74   24   110   124   172         
  *p* value (ED)                0.631 (+)                      1 (FET)                        0.887 (-)                      0.806 (+)                1 (FET)                        0.887 (-)                      0.841 (+)                      0.207 (+)                      0.469 (FET) (+)           0.920 (+)                                                                                                      
  **2DL4**                                                                                                                                                                                                                                                                                                                                                                                                                  
  **2DL5**                      16                             20                             35                             28                       5                              12                             36                             148                            37                        33                        127                            151             32   56   4    50    79    103   58   60
  *p* value (ED)                0.680 (-)                      0.521 (+)                      1 (FET)                        0.005 (-)                0.610 (+)                      0.238 (+)                                                     0.072 (+)                      0.032 (-)                 0.537 (+)                 0.887 (-)                                                                            
  **3DL1**                      50                             48                             73                             67                                                                                     88                             256                            64                        63                        120                            191             36   81   24   117   125   185   93   95
  *p* value (ED)                0.162 (FET) (+)                1 (FET)                                                       0.502 (-)                0.999 (FET) (+)                0.0001 (-)                                                    1 (FET)                        1 (FET)                   0.131 (-)                 0.764 (-)                                                                            
  **3DL2**                                                                                                                                                                                                                                                                                                                                                                                                                  
  **3DL3**                                                                                                                                                                                                                                                                                                                                                                                                                  
  **2DS1**                      21                             25                             44                             28                       1                              4                              24                             121                            32                        26                        92                             88    35   48   21   31   8    58    63    73    49   40
  *p* value (ED)                0.740 (-)                      0.035 (+)                      1 (FET)                        0.001 (-)                0.386 (+)                      0.283 (+)                      0.084 (-)                      0.005 (+)                      0.228 (-)                 0.182 (+)                 0.254 (+)                                                                            
  **2DS2**                      27                             26                             22                             18                       1                              3                              46                             140                            45                        39                        104                            72    50   58   26   41   14   69    69    97    59   54
  *p* value (ED)                0.777 (+)                      0.764 (+)                      1 (FET)                        0.624 (-)                0.377 (+)                      0.001 (+)                      0.319 (-)                      0.063 (+)                      0.806 (+)                 1                         0.565 (+)                                                                            
  **2DS3**                      16                             15                             25                             20                       2                              3                              22                             70                             22                        24                        94                             66              17   29   11   40    44    55    38   34
  *p* value (ED)                0.824 (+)                      0.622 (+)                      0.613 (+)                      0.680 (-)                0.862 (-)                      0.0007 (+)                                                    0.350 (+)                      0.399 (+)                 0.577 (+)                 0.654 (+)                                                                            
  **2DS4**                      18                             21                             72                             65                       8                              24                             90                             255                            62                        64                        109                            163             36   82   25   117   130   185   95   95
  *p* value (ED)                0.862 (-)                      0.352 (FET) (+)                0.777 (-)                      1 (FET)                  0.740 (-)                      0.0001 (-)                                                    1 (FET)                        0.588 (FET) (+)           0.777 (-)                 1                                                                                    
  **2DS5**                      10                             18                             38                             26                       4                              8                              23                             102                            30                        19                        122                            122             22   35   6    37    53    70    35   34
  *p* value (ED)                0.171 (-)                      0.139 (+)                      0.722 (FET) (+)                0.021 (-)                0.074 (+)                      0.337 (+)                                                     0.129 (+)                      0.698 (-)                 0.764 (+)                 1                                                                                    
  **3DS1**                      17                             20                             38                             32                                                                                     24                             121                            34                        23                        162                            116             16   37   7    46    62    77    41   40
  *p* value (ED)                0.590 (-)                      0.761 (+)                                                     0.001 (-)                0.082 (+)                      0.0001 (+)                                                    0.920 (-)                      0.488 (-)                 0.409 (+)                 1                                                                                    
  **2DP1**                                                                                                                                                                                                                                                                                                                                                                                                                  
  **3DP1**                                                                                                                                                                                                                                                                                                                                                                                                                  
  Study design                  Case-control                   Case-control                   Case-control                   Case-control             Case-control                   Case-control                   Case-control                   Case-control                   Case-control              Cohort for KIR2DS1        Case-control                                                                         
  Genotyping method             PCR-SSP                        PCR-SSP                        PCR-SSP                        PCR-SSP                  PCR-SSO                        PCR-SSP                        PCR-SSP                        PCR-SSO                        PCR-SSP                   PCR-SSO                   PCR-SSP                                                                              
  RSA definition                3 spontaneous abortion         3 spontaneous abortion         3 spontaneous abortion         3 spontaneous abortion   3 spontaneous abortion         3 spontaneous abortion         3 spontaneous abortion         A history of miscarriage       Any fertility problem     2 spontaneous abortion    3 spontaneous abortion                                                               
  Control definition            2 history of normal delivery   2 history of normal delivery   2 history of normal delivery   Any primiparous woman    2 history of normal delivery   2 history of normal delivery   1 history of normal delivery   2 history of normal delivery   Not mentioned             Not  mentioned            2 history of normal delivery                                                         
  Place                         Brazil                         China                          China                          London                   Brazil                         India                          Iranian                        Mediterranean                  Albania                   America                   Iran                                                                                 
  Ethnicity                     Caucasian                      Chinese                        Chinese                        Caucasian                Caucasian                      Indian                         Caucasian                      Caucasian                      Caucasian                 Caucasian                 Caucasian                                                                            
  Study number in dendrogram    1                              2                              3                              4                        5                              6                              7                              8                              9                         10                        11                                                                                   

a\) ED stands for effect direction; the positive ones show risk factors and the negative ones show protecting factors.

b\) FET stands for Fisher\'s exact test.

Statistical analysis
--------------------

To perform the present meta-analysis, we used the comprehensive meta-analysis version 2 software (Biostat, US). The analyses were carried out through a *p* value and individual sample size using fixed-effect and random-effect models. Since the *p* values were calculated using Yate\'s correction (or Fisher\'s exact test if necessary), the odds ratios (OR) (effect sizes) achieved from these *p* values were underestimated. This statistical protocol has been previously published ([@r34]).

Heterogeneity and publication bias
----------------------------------

We used the *I^2^* scale and *I^2^*\<50 was considered as homogeneity. In the cases of heterogeneity, we used the random-effect model. In order to find publication bias, we used funnel plots. If a study were to be find outside the funnel, it meant that its effect size was outside the expected 95% confidence interval (CI). In other words, its difference with other studies is statistically significant at *p*=0.05. Hence, a publication bias does not have necessarily a negative connotation. In the present study, a funnel plot *p* value \< 0.05 means that the mentioned individual study is outside the funnel of 95% CI.

Additional analyses
-------------------

In order to cluster the studies for meta-analysis, we designed a dendrogram using the STATA14 software (StataCorp LLC, US). This cluster analysis involved the complete linkage of binary variables ([Table 2](#t2){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}).

Figure 1Cluster analysis of [Table 2](#t2){ref-type="table"} based on complete linkage method. The numbers of studies are based on [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}.

###### 

Dissimilarity matrix of studies\' characteristics based on the below of [Table 1](#t1){ref-type="table"}

                                    Witt *et al*., 2004   Wang *et al*., 2007   Hong *et al*., 2008   Hiby *et al*., 2008   Vargas *et al*., 2009   Faridi *et al*., 2009   Khosravifar *et al*., 2011   Ozturk *et al*., 2012   Djulejic *et al*., 2015   Dambaeva *et al*. 2016   Our study
  ---- ---------------------------- --------------------- --------------------- --------------------- --------------------- ----------------------- ----------------------- ---------------------------- ----------------------- ------------------------- ------------------------ -----------
  1    Witt *et al*., 2004          0                     0.33                  0.33                  0.33                  0.16                    0.33                    0.33                         0.50                    0.50                      0.83                     0.16
  2    Wang *et al*., 2007          0.33                  0                     0                     0.50                  0.50                    0.33                    0.50                         0.66                    0.66                      1                        0.33
  3    Hong *et al*., 2008          0.33                  0                     0                     0.50                  0.50                    0.33                    0.50                         0.66                    0.66                      0.83                     0.33
  4    Hiby *et al*., 2008          0.33                  0.50                  0.50                  0                     0.50                    0.50                    0.33                         0.66                    0.50                      0.83                     0.33
  5    Vargas *et al*., 2009        0.16                  0.50                  0.50                  0.50                  0                       0.50                    0.50                         0.33                    0.66                      0.66                     0.33
  6    Faridi *et al*., 2009        0.33                  0.33                  0.33                  0.50                  0.50                    0                       0.50                         0.66                    0.66                      1                        0.33
  7    Khosravifar *et al*., 2011   0.33                  0.50                  0.50                  0.33                  0.50                    0.50                    0                            0.66                    0.50                      0.83                     0.33
  8    Ozturk *et al*., 2012        0.50                  0.66                  0.66                  0.66                  0.33                    0.66                    0.66                         0                       0.66                      0.66                     0.50
  9    Djulejic *et al*., 2015      0.50                  0.66                  0.66                  0.50                  0.66                    0.66                    0.50                         0.66                    0                         0.66                     0.50
  10   Dambaeva *et al*., 2016      0.83                  1                     0.83                  0.83                  0.66                    1                       0.83                         0.66                    0.66                      0                        0.83
  11   Our original study           0.16                  0.33                  0.33                  0.33                  0.33                    0.33                    0.33                         0.50                    0.50                      0.83                     0

RESULTS
=======

Eligible studies
----------------

[Table 1](#t1){ref-type="table"} depicts the findings from the selected studies, in addition to our original case-control study, this table includes 11 studies. The *p* values were analyzed through Yate\'s correction (or fisher\'s exact test when necessary). Positive effect directions show each gene as a risk factor and negative effect directions show each gene as a protecting factor. Our cluster analysis showed that the study by Dambaeva *et al*. (2016) had a different design in comparison to other studies ([Figure 1](#f1){ref-type="fig"}). Hence, it was excluded from the meta-analysis. At the end, 10 studies remained.

Meta-analysis
-------------

The role of *KIR2DL1* in RSA was not statistically significant (*p*=0.051; OR=0.849; fixed). [@r7] showed a significantly more protective effect of this gene in comparison to other studies (funnel plot *p* value \<0.05) ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}).

Figure 2KIR2DL1 Funnel plot showing a significant bias for [@r7].

Figure 3Forest plot of KIR2DL1 (fixed). Favours A shows protecting effect and favours B shows harmful effect (in all figures).

The role of *KIR2DL2* in RSA was not statistically significant (*p*=0.325; OR=1.091; fixed). [@r12] showed a significantly higher risk of this gene\'s effect in comparison to other studies (funnel plot *p* value \<0.05) ([Figures 4](#f4){ref-type="fig"} and [5](#f5){ref-type="fig"}). The role of *KIR2DL3* in RSA was not statistically significant (*p*=0.448; OR=1.062; fixed). No publication bias was found based on the funnel plot ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}). The role of *KIR2DL5* in RSA was not statistically significant (*p*=0.767; OR=0.960; random). [@r11] showed a significantly more protective effect of this gene in comparison to other studies (funnel plot *p* value \<0.05) ([Figures 8](#f8){ref-type="fig"} and [9](#f9){ref-type="fig"}).

Figure 4KIR2DL2 Funnel plot showing a significant bias for [@r12].

Figure 5Forest plot of KIR2DL2 (fixed).

Figure 6Funnel plot of KIR2DL3 shows no publication bias.

Figure 7KIR2DL3 Forest plot (fixed).

Figure 8KIR2DL5 Forest plot showing a significant bias for [@r11] study.

Figure 9KIR2DL5 Forest plot (random).

The role of *KIR3DL1* in RSA was statistically significant (*p*=0.044\*; OR=0.833; fixed). [@r7] showed a significantly more protective effect of this gene in comparison to other studies (*p*\<0.05; based on funnel plot) ([Figures 10](#f10){ref-type="fig"} and [11](#f11){ref-type="fig"}). The role of *KIR2DS1* in RSA was not statistically significant (*p*=0.726; OR=1.056; random). Inconclusive publication bias was found for this analysis based on the funnel plot ([Figures 12](#f12){ref-type="fig"} and [13](#f13){ref-type="fig"}). The role of *KIR2DS2* in RSA was statistically significant (*p*=0.034\*; OR=1.195; fixed). Faridi *et al.* (2009) study showed significantly more risk effect of this gene in comparison to other studies (funnel plot value \<0.05) ([Figures 14](#f14){ref-type="fig"} and [15](#f15){ref-type="fig"}). The role of *KIR2DS3* in RSA was statistically significant (*p*=0.013\*; OR=1.246; fixed). [@r7] showed significantly more risk effect of this gene in comparison to other studies (funnel plot *p* value \<0.05) ([Figures 16](#f16){ref-type="fig"} and [17](#f17){ref-type="fig"}).

Figure 10KIR3DL1 Funnel plot showing a significant bias for [@r7].

Figure 11KIR3DL1 Forest plot (fixed).

Figure 12KIR2DS1 Funnel plot showing a huge publication bias which is inconclusive.

Figure 13KIR2DS1 Forest plot (random).

Figure 14KIR2DS2 Funnel plot showing a significant bias for Faridi et al. (2009).

Figure 15KIR2DS2 Forest plot (fixed).

Figure 16KIR2DS3 Funnel plot showing a rather significant bias for [@r7].

Figure 17KIR2DS3 Forest plot (fixed).

The role of *KIR2DS4* in RSA was not statistically significant (*p*=0.094; OR=0.762; fixed). [@r7] showed significantly more protective effect of this gene in comparison to other studies (funnel plot *p* value \<0.05) ([Figures 18](#f18){ref-type="fig"} and [19](#f19){ref-type="fig"}). The role of *KIR2DS5* in RSA was not statistically significant (*p*=0.642; OR=1.042; fixed). [@r11] showed a significantly more protective effect of this gene in comparison to other studies (funnel plot *p* value \<0.05) ([Figures 20](#f20){ref-type="fig"} and [21](#f21){ref-type="fig"}). The role of *KIR3DS1* in RSA was not statistically significant (*p*=0.851; OR=1.037; random). [@r11] and Faridi *et al*. (2009) showed significantly more protective and risk effect of this gene in comparison to other studies, respectively (funnel plot *p* value \<0.05) ([Figures 22](#f22){ref-type="fig"} and [23](#f23){ref-type="fig"}).

Figure 18Funnel plot of KIR2DS4 shows a significant bias for [@r7].

Figure 19KIR2DS4 Forest plot (fixed).

Figure 20KIR2DS5 Funnel plot showing a significant bias for [@r11].

Figure 21KIR2DS5 Forest plot (fixed).

Figure 22KIR3DS1 Funnel plot showing a significant bias for [@r11] and [@r7].

Figure 23KIR3DS1 Forest plot (random).

DISCUSSION
==========

Summary of evidence
-------------------

NKs are lymphocytes that participate in the innate immune system. They have 2 subtypes: CD16^+^CD56^dim^ and CD16^-^CD56^bright^ that are called as cytotoxic and immune-regulatory NKs, respectively. In the implantation site, the NKs are mainly CD56^bright^. Hence, the immune system has a positive and protecting role in implantation and early pregnancy. Embryo implantation and pregnancy are a type of transplantation called semi-allograft. Thus, we need immune tolerance to have a successful pregnancy. The NKs play their roles with their KIRs interacting with the HLAs expressed on trophoblasts ([@r31]). Because of the important roles of NKs in the implantation process, this meta-analysis aimed to investigate the role of maternal *KIR* genes diversity in RSA.

Among the investigated genes, only the results of *3DL1, 2DS2* and *2DS3* were statistically significant with protective, risk and risk effect impacts, respectively ([Table 3](#t3){ref-type="table"}). If we adjust multiple test correction for these findings, none of them would remain significant. It shows that there is no specific *KIR* gene predicting RSA. The funnel plot analyses showed that [@r7], in India, had more publication bias in comparison to the others. In our study we showed that maternal *KIR2DS1* in combination with paternal *HLA-C2* can be a risk factor ([@r1]).

###### 

The pooled results of the meta-analsis. In the cases I2\>50 random effect model has also been performed.

  Pooled     Fixed effect   Random effect                                                  
  ---------- -------------- --------------------------------------- ------- ------ ------- -------
  **2DL1**   20.92          0.051                                   0.849   \-     \-      \-
  **2DL2**   36.59          0.325                                   1.091   \-     \-      \-
  **2DL3**   0.00           0.448                                   1.069   \-     \-      \-
  **2DL4**                                                                                  
  **2DL5**   53.79          0.521                                   0.945   0.00   0.767   0.960
  **3DL1**   47.16          0.044[\*](#TFN3){ref-type="table-fn"}   0.833   \-     \-      \-
  **3DL2**                                                                                  
  **3DL3**                                                                                  
  **2DS1**   70.31          0.990                                   0.999   0.00   0.726   1.058
  **2DS2**   25.97          0.034[\*](#TFN3){ref-type="table-fn"}   1.195   \-     \-      \-
  **2DS3**   0.00           0.013[\*](#TFN3){ref-type="table-fn"}   1.246   \-     \-      \-
  **2DS4**   40.36          0.094                                   0.862   \-     \-      \-
  **2DS5**   48.52          0.642                                   1.042   \-     \-      \-
  **3DS1**   75.82          0.525                                   1.059   0.00   0.851   1.037
  **2DP1**                                                                                  
  **3DP1**                                                                                  

significant at 0.05

Literature review
-----------------

This concern in reproductive immunology dates back to 2004. [@r30] found no significant association of maternal *KIR* genes with the risk of RSA in a Brazilian population. Lack of paternal or fetal evaluation of *HLA-C* was their study limitation. [@r33] evaluated different immune markers such as CD94, CD158 (the very KIR) and CD161 through flow cytometry in 20 RSA women and 15 fertile controls. They found a lower level of CD158a (the very KIR2DL1) in the RSA group. Their low sample size was a limitation in their study ([@r33]). Because of their quantitative approach and different aims and protocols, we excluded that study from our meta-analysis. [@r28] evaluated only *KIR2DL1, 2DL2* and *2DL3* among the *KIR* genes in a small sample size. [@r29] found a risk association for *KIR2DS1* in a Chinese population. They evaluated *HLA-C* in couples, similar to our original experience. Conversely, our original study and some studies before, e.g. [@r11], found a strongly protecting association for *KIR2DS1* in a Caucasian population. However, since their control group criteria was to be a first-birth woman, this might be the reason of their publication bias. [@r27] found a risk association for the number of maternal activating *KIR* genes. [@r7] found that RSA was more associated with activating, and more protected with inhibitory *KIR* genes. [@r19] found that RSA could be associated with *KIR* genotypes. Conversely, other studies found that RSA was more frequent in patients with genotypes bearing 6 inhibitory genes. Because we did not have access to the frequencies of *KIR* genes, we excluded this study from our meta-analysis. [@r20] found that female heterozygosity for *HLA-C* in combination with *AA* KIR genotype could be a protecting factor for RSA. [@r14] investigated the role of maternal *KIR* and parental *HLA-C* in an Iranian population. They found that RSA was associated with maternal *HLA-C2*. [@r22] found a protecting role for the KIR *AA* genotype. A small sample size and one miscarriage episode in the RSA group were the negative points of their study. [@r2]) found that maternal *AA* genotype was a risk factor affecting the success of double embryo transformation. [@r6]) evaluated the role of *KIR* genes on women with any fertility problem. Hence, we excluded it from our meta-analysis. [@r21] investigated the role of *KIR2DL4* and *HLA-G* polymorphisms in RSA. [@r5] showed that maternal *KIR2DS1* is not a risk factor for RSA by itself, rather its combination with maternal *HLA-C2* could be associated.

Interpretation
--------------

As we observe above, there are many paradoxical findings for the role of maternal *KIR* genes in RSA. This can be justified through reasons like different ethnicities, different sample sizes, different RSA group criteria, different control criteria, and so on. In all the studies in [Table 1](#t1){ref-type="table"}, the genotyping method used was polymerase chain reaction with sequencing specific primers (PCR-SSP), and PCR with sequence specific oligonucleotides (PCR-SSO). Therefore, the genotyping method cannot be a reason for such paradoxes. Other features likely to be involved with this paradox are shown as a cluster analysis ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}).

The results of *KIR2DS1* had more publication bias based on funnel plots than the present meta-analysis. A paradoxical piece of evidence is that in early pregnancy KIR2DS1 is a helping factor (contrary to some studies), because its activating role (especially in combination with trophoblast HLA-C2) results in higher cytokine releasing of UNKs ([@r32]). Hence, it seems that this receptor has a protecting role for implantation and placentation, and is a risk factor for late pregnancy maintenance. For instance, [@r2] found that maternal *AA* genotype was a risk factor for the success of assisted reproduction. *AA* is the most inhibitory genotype and therefore it supports this hypothesis that NK activation is necessary in early pregnancy. Pregnancy loss has numerous causes, in particular embryo genetic and chromosomal abnormalities. Therefore, the immune system\'s theoretical role is to reject such malformed embryos. Therefore, this risky role of activating KIRs is in fact a protecting role! Of course, it is remarkable that the lack of genetic evaluation of the lost embryos was a limitation for the studies imported to this meta-analysis. It is suggested that this variable should be adjusted in future studies.

Limitations
-----------

Although we found significant associations involving 3 genes in the meta-analysis ([Table 3](#t3){ref-type="table"}), but these findings would not be reliable, because, 1) the odds ratios are not large enough to show a remarkable effect size; 2) the paper selection and homogenizing process of meta-analyses are different and customized among researchers; 3) there were a lot of missed data even in the cited studies; 4) pregnancy loss has a number of definitions such as abortion, stillbirth ([@r9]) and assisted reproduction failure ([@r16]), and happens because due to conditions such as the anti-phospholipid syndrome (APS) ([@r24]), and there might be confusion involving these concepts. Adjusting models in future studies help researchers solve these limitations.

CONCLUSION
==========

The role of maternal *KIR* gene diversity in RSA is still in unclear, although our meta-analysis showed 3 genes as associated factors. *KIR3DL1* was a protecting factor, and *KIR2DS2* and *KIR2DS3*, which proved to be risk factors for RSA. For *KIR2DS1* there was a high heterogeneity. It seems that its role is different among different causes of pregnancy loss. Our previous case-control original investigation showed a significant relation with maternal *KIR2DS1* in combination with paternal *HLA-C2* as a risk factor. In order to clarify this role we have some suggestions for future studies, such as investigations of this combination concerning the success rate of assisted reproduction, for early first trimester abortions occurring after implantation and early placentation, for stillbirth groups, for abortions secondary to APS, and for successful and unsuccessful pregnancies of malformed embryos and fetuses. We would also like to suggest adjusting models and cohort studies.
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